What is HC Wainwright’s Estimate for BioLineRx Q3 Earnings?

BioLineRx Ltd. (NASDAQ:BLRX) – Equities research analysts at HC Wainwright increased their Q3 2024 earnings per share (EPS) estimates for BioLineRx in a research report issued to clients and investors on Wednesday, November 6th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will earn ($0.03) per share for the quarter, up from their prior forecast of ($0.17). HC Wainwright currently has a “Buy” rating and a $21.00 target price on the stock. The consensus estimate for BioLineRx’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for BioLineRx’s Q4 2024 earnings at ($0.04) EPS, FY2024 earnings at ($0.04) EPS and FY2025 earnings at ($0.10) EPS.

Separately, StockNews.com started coverage on BioLineRx in a research report on Friday. They issued a “hold” rating for the company.

BioLineRx Price Performance

BLRX stock opened at $0.45 on Friday. The firm has a market capitalization of $36.08 million, a PE ratio of -1.00 and a beta of 1.48. BioLineRx has a 1 year low of $0.39 and a 1 year high of $1.93. The company has a debt-to-equity ratio of 1.34, a current ratio of 1.61 and a quick ratio of 1.49. The business has a 50 day simple moving average of $0.53 and a 200-day simple moving average of $0.63.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings results on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. The company had revenue of $5.39 million during the quarter, compared to analysts’ expectations of $3.93 million.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in BLRX. CVI Holdings LLC purchased a new position in BioLineRx in the second quarter worth approximately $462,000. PVG Asset Management Corp acquired a new position in BioLineRx during the second quarter worth $70,000. Finally, Atria Investments Inc lifted its stake in BioLineRx by 27.9% during the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 29,193 shares in the last quarter. 1.56% of the stock is currently owned by hedge funds and other institutional investors.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.